share_log

Cowen & Co. Upgrades Takeda Pharmaceutical to Outperform, Raises Price Target to $24

Cowen & Co. Upgrades Takeda Pharmaceutical to Outperform, Raises Price Target to $24

Cowen & Co.將武田製藥上調至跑贏大盤,將目標股價提高至24美元
Benzinga Real-time News ·  2022/07/19 07:54

Cowen & Co. analyst Ken Cacciatore upgrades Takeda Pharmaceutical (NYSE:TAK) from Market Perform to Outperform and raises the price target from $21 to $24.

Cowen & Co. 分析師肯·卡恰託雷將武田製藥(紐約證券交易所代碼:TAK)從市場表現上調至跑贏大盤,並將目標股價從21美元上調至24美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論